Board of Directors
With 15 years of management experience in both established and start-up companies and seven years practicing law as an associate and partner at a large, mid-South law firm (Jones, Walker, Waechter, Poitevent, Carrère and Denègre). Jay has a unique and diverse background for the assessment and operation of emerging technologies and startups in the life sciences sector.
Prior to joining Finistere in July 2005, Jay was most recently President and Chief Executive Officer of Advanced Stent Technologies (AST), a medical device startup focused on developing and commercializing a proprietary stent system for the treatment of coronary artery bifurcation disease. Under his leadership, AST was sold to Boston Scientific Corporation ( BSC ) in March 2005.
Prior to AST, Jay held several positions with a large US-based agri-chemical company. His last position was Vice President of Strategic Initiatives where he was responsible for identifying emerging technology investment and partnering opportunities in the agbio and agritech fields.
Jay is Chairman of the Board of Directors of Catharos Medical Systems, Inc. and serves on the Boards of Generic Medical Devices, Inc., Hotspur Technologies, Inc., nContact Surgical, Inc. and Luminous, Inc. Jay is also a board observer on Sadra Medical, Inc. and Transcend Medical, Inc.
Fred Khosravi is a Silicon Valley medical device entrepreneur who has co-founded eight companies, including EndoTex, Embolic Protection, Inc. (EPI), both acquired by Boston Scientific Corporation, Confluent Surgical, acquired by Tyco Healthcare, and MarketRx, acquired by Cognizant Corp. Additionally, he is the managing director of a medical device incubator called Incept. In addition to Confluent, EPI, and AccessClosure, Inc, Incept has spawned several other novel device companies including Sadra Medical, Ostial Corp., Hotspur Technologies, Inc., and Ocular Therapeutix, Inc., where Fred serves as co-founder and Director/Chairman. Fred also served on the boards of Kerberos before its acquisition by FoxHollow Technologies and Advanced Stent Technologies prior to its acquisition by Boston Scientific. He holds a B.S. in mechanical engineering, and graduated summa cum laude, obtaining a M.S. in mechanical engineering from Tennessee Tech University.
Rob Kuhling came to ONSET Ventures in 1987 after experience in a variety of technology marketing, strategic development and management positions. Rob was Director of Marketing at Sun Microsystems, where he spearheaded the company's expansion into the design automation marketplace. He also served as VP and Manager of General Electric-Calma's $100 million electronic design automation business and was a team leader for Boston Consulting Group, where he oversaw the development of a range of corporate business strategies.
At ONSET Ventures, Rob invests in communications and networking companies and medical device companies. Rob serves on the boards of several public and private companies, and has led ONSET Ventures' investments in companies like Aneurx, Clarify, Conceptus, Alteon, Packeteer, Embolic Protection, Endotex Interventional Systems, and Gadzoox Networks. Rob's current board memberships are Access Closure, Baronova, Hotspur Technologies, Inc. and Uptake Medical.
Rob received his A.B. from Hamilton College and his MBA from Harvard Business School.
Renee Masi :
Renee Masi has over 20 years of experience in the venture capital industry where she focused most recently on life science investing. Ms. Masi also serves on the boards of SynergEyes, Axis Surgical and CardiacMD. Prior to joining BioStar Ventures, Ms. Masi was a Partner with Windward Ventures, a firm focused on southern California early stage companies, where Ms. Masi was responsible for the firm's life science investing strategy. Ms. Masi was an advisor to Ventures Medical, a seed stage fund affiliated with the Texas Medical Center. In 1990 Ms. Masi opened the Boston office for Technology Funding, a $250 million venture capital fund based in San Mateo, California. Ms. Masi began her career as an investment banker in the health care finance group of Merrill Lynch. In addition to holding a BA from Stanford University and an MBA from The Wharton School of Business, Ms. Masi is also a member of the Board of Councilors for the USC Graduate School of Social Work and the Development Committee for Park Century School.
William G. Mavity :
William G. Mavity joined Paracor Medical, Inc. as President, Chief Executive Officer, and Director in March, 2003, and currently serves as Chairman/CEO. Paracor Medical is focused on developing device based treatments for patients suffering from heart failure.
From September 2001 to January 2003, he served as President, CEO, and a Director of Cohesion Technologies, Inc., a publicly-traded biomaterials company that was acquired by Angiotech Pharmaceuticals, Inc. in January 2003 for more than $42 million. From March 2001 until September 2001, Mr. Mavity led the spinout and initial organization and funding of Biosurface Engineering Technologies, Inc. as its Chairman, CEO and Director.
Prior to the creation of BioSET, he served as President, CEO, and a Director of InnerDyne, Inc. and its predecessor organization, CardioPulmonics, Inc. InnerDyne, a publicly traded medical device company, was formed through the merger of privately held InnerDyne Medical with publicly held CardioPulmonics in 1994. InnerDyne was acquired by the United States Surgical unit of Tyco International in December 2000 for almost $190 million. From 1972 until 1993, Mr. Mavity served in various operations and general management roles with the 3M Company, including heading its cardiovascular subsidiary, Sarns/3M Health Care, and serving as the head of European Health Care manufacturing.
Mr. Mavity holds a Bachelor of Engineering Administration degree from the University of Delaware (1972), and did graduate study in Business Administration at Rider College and Furman University. He also served as an officer in the U. S. Army Reserve, Corps of Engineers, from 1973 until 1983.
In addition to his role at Paracor Medical, Mr. Mavity currently serves as the Chairman of the Board of Biosurface Engineering Technologies, Inc. and as a Director of USGI Medical, Inc. He has previously served on the Boards of Cohesion Technologies, Inc., InnerDyne, Inc., Cardeon, Inc., AMed Sytems, Inc., Aspire Medical, Inc., Fidus Medical Technologies, NeuColl, Inc. and the Michigan Technology Council. Mr. Mavity also serves on the Advisory Council for the College of Engineering at the University of Delaware.
Gwen Watanabe is a serial entrepreneur who has worked at Hotspur Technologies, Inc., serving as President & CEO since March 2009. Prior to her time at Hotspur, Ms. Watanabe served as Co-Founder and Chief Business Officer at Nellix Endovascular, a company that develops endografts in the AAA and TAA treatment space. Other early-stage companies that Gwen has been involved in include AneuRx (acquired by Medtronic) and Bacchus Vascular (acquired by Covidien).
Gwen has a B.S. in Mechanical Engineering from Massachusetts Institute of Technology, an M.S. in Mechanical Engineering from Stanford University, and an MBA from Harvard Business School.